Donald E. Ingber, M.D., Ph.D. is the Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard University, Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children’s Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences. He received his B.A., M.A., M.Phil., M.D. and Ph.D. from Yale University.
Ingber is a pioneer in the field of biologically inspired engineering, and at the Wyss Institute, he currently leads a multifaceted effort to develop breakthrough bioinspired technologies to advance healthcare and to improve sustainability. His work has led to major advances in mechanobiology, tumor angiogenesis, tissue engineering, systems biology, nanobiotechnology and translational medicine. Through his work, Ingber also has helped to break down boundaries between science, art and design.
Ingber has authored more than 450 publications and over 120 issued or pending patents, founded 5 companies, and been a guest speaker at more than 500 events internationally. He is a member of the National Academy of Medicine, National Academy of Inventors, American Institute for Medical and Biological Engineering, and the American Academy of Arts and Sciences. He was named one of the Top 20 Translational Researchers world-wide in 2012 (Nature Biotechnology), a Leading Global Thinker of 2015 (Foreign Policy magazine), and has received numerous other honors in a broad range of disciplines, including the Robert A. Pritzker Award and the Shu Chien Award (Biomedical Engineering Society), the Rous Whipple Award (American Society for Investigative Pathology), the Lifetime Achievement Award (Society of In Vitro Biology), the Leading Edge Award (Society of Toxicology), Founders Award (Biophysical Society) and the Department of Defense Breast Cancer Innovator Award.
One example of Ingber’s most recently developed technologies are Human Organs-on-Chips. These are microfluidic cell culture devices created with microchip manufacturing methods and lined by living human cells, which are being used to replace animal testing as a more accurate and affordable in vitro platform for drug development and personalized medicine. In 2013, Ingber’s work on Organs-on-Chips was honored by the NC3Rs Annual Award from the National Centre for the Replacement, Refinement, and Reduction of Animals in Research, London; in 2015, this technology was named Design of the Year by the London Design Museum and was also acquired by the Museum of Modern Art (MoMA) in New York City for its permanent design collection; and in 2016, they were named one of the Top 10 Emerging Technologies of 2016 by the World Economic Forum.